Coskun, GoekhanOzde, CemKayapinar, OsmanAktore, GulsahEksi, EnsarAfsin, HamdiSayin, Ahmet Egemen2024-08-232024-08-2320241076-02961938-2723https://doi.org/10.1177/10760296241237232https://hdl.handle.net/20.500.12684/14073Background: The anticoagulation and risk factors in atrial fibrillation (ATRIA) score is associated with adverse cardiovascular events. However, its relationship with coronary thrombus burden is unclear. Therefore, we aimed to investigate the relationship between the ATRIA score and thrombus burden in patients with ST-segment elevation myocardial infarction (STEMI) who underwent percutaneous coronary intervention (PCI). Materials and Methods: The study was designed as a prospective cross-sectional observational study. Our study included 319 patients who were prospectively admitted with STEMI between January 2021 and April 2022. Patients were divided into 2 groups with low thrombus burden (LTB) (grade <3) and high thrombus burden (HTB) (grade >= 3). ATRIA score was calculated and recorded for all patients. ATRIA scores of both groups were compared. Results: In our study, 58.9% (n = 188) of patients in the LTB group and 41% (n = 131) of patients in the HTB group. The ATRIA risk score (p < .001) was significantly higher in the HTB group. In multivariate logistic regression analysis, ATRIA score, glomerular filtration rate, hypertens & imath;on, abciximab usage, and no-reflow were found to be independent predictors of HTB in STEMI patients undergoing primary PCI. In receiver operating characteristic analysis, ATRIA score >4 had a sensitivity of 66.2% and specificity of 95.2%, and ATRIA score >8 sensitivity of 98% and specificity of 100% predicted HTB. Conclusion: In this study, we found that thrombus burden may be associated with ATRIA risk score in patients presenting with STEMI.en10.1177/10760296241237232info:eu-repo/semantics/openAccessATRIA scorethrombus burdenST-segment elevation myocardial infarctionNo-Reflow PhenomenonPredicting StrokeEuropean-SocietyTask-ForceCha(2)Ds(2)-VascInterventionHypertensionGuidelinesMortalityDamageArticle30386447742-s2.0-85191102965WOS:001206379500001Q2N/A